Mylan's Troubles Just Won't Stop Showing Up

Published: Nov 07, 2016

Pharmaceutical maker Mylan (MYL) is the target of yet another set of questions on its pricing practices. This time, though, its controversial autoinjector EpiPen was spared headlines.

Bloomberg and Wall Street Journal reported Thursday that the Department of Justice is investigating several generic drug makers on allegations of pricing collusion, which sent the group's stocks plummeting. The DOJ's investigation has been under way for at least two years and a number of companies have reported receiving subpoenas related to the investigation.

Back to news